Table 5 The correlation between the clinical information and metabolic parameters of 37 PMR patients and the degree of pathological regression after neoadjuvant immunochemotherapy
Characteristic | Non-MPR (n = 12) | MPR (n = 25) | P |
|---|---|---|---|
Age (year) | 59.58 ± 7.34 | 62.20 ± 7.11 | 0.307 |
Sex (male/female) | 8/4 | 24/1 | 0.03 |
TPS | 12.33 ± 20.28 | 18.86 ± 31.27 | 0.886 |
Clinical stage | - | - | 0.146 |
Scan-1 | |||
SULmax | 11.7 ± 5.8 | 11.3 ± 4.9 | 0.911 |
SULpeak | 9.7 ± 4.8 | 9.9 ± 4.5 | 0.886 |
MTV | 41.5 ± 67.6 | 30.3 ± 23.5 | 0.643 |
TLG | 232.6 ± 356.5 | 212.7 ± 188.0 | 0.395 |
T/N ratio | 5.6 ± 2.9 | 5.4 ± 2.3 | 0.987 |
Scan-2 | |||
SULmax | 4.4 ± 2.3 | 2.1 ± 0.9 | <0.001 |
SULpeak | 3.3 ± 1.8 | 1.8 ± 1.0 | 0.001 |
MTV | 44.2.±67.1 | 66.5 ± 10.9 | 0.761 |
TLG | 15.8 ± 29.6 | 14.1 ± 42.2 | 0.181 |
T/N ratio | 1.8 ± 1.0 | 0.9 ± 0.4 | <0.001 |
The percentage changes(Δ%) between scan-1 and scan-2 | |||
ΔSULmax% | -56.6 ± 20.1 | 78.7 ± 11.3 | 0.001 |
ΔSULpeak% | -59.9 ± 19.7 | -78.9 ± 13.1 | 0.003 |
ΔMTV% | -78.1 ± 24.7 | -81.3 ± 19.2 | 0.886 |
ΔTLG% | -88.4 ± 13.9 | -94.8 ± 6.7 | 0.077 |
ΔT/N ratio% | -62.7 ± 18.7 | -81.0 ± 9.8 | 0.002 |